Hims & Hers
Hims & Hers Stock Tanks After Novo Nordisk Deal Ends
Hims & Hers Health (ticker: HIMS), a rising telehealth and wellness company, saw its stock plunge roughly 30–35% on Monday. The drop followed Novo Nordisk abruptly canceling their partnership, accusing Hims of promoting and selling unauthorized compounded versions of Wegovy—semaglutide’s weight-loss version—putting patients at risk.